DECIPHERA PHARMACEUTICALS, INC. Financials Deciphera Pharmaceuticals, Inc.
Equities
DCPH
US24344T1016
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.38 USD | 0.00% |
|
+73.24% | +57.35% |
| 01/05 | North American Morning Briefing : Traders Wait for -2- | DJ |
| 30/04 | Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,177 | 3,249 | 571.4 | 1,108 | 1,292 | 2,087 | - | - |
| Enterprise Value (EV) 1 | 2,597 | 2,697 | 484.3 | 1,043 | 1,212 | 2,087 | 2,087 | 2,087 |
| P/E ratio | -13.9 x | -11.9 x | -1.89 x | -6.92 x | -7.04 x | -11.6 x | -15.4 x | -34.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 127 x | 77.2 x | 5.94 x | 8.26 x | 7.91 x | 10.4 x | 7.92 x | 5.57 x |
| EV / Revenue | 127 x | 77.2 x | 5.94 x | 8.26 x | 7.91 x | 10.4 x | 7.92 x | 5.57 x |
| EV / EBITDA | -1,58,93,127 x | -1,20,83,939 x | -19,23,355 x | -61,60,841 x | -61,87,870 x | - | - | - |
| EV / FCF | -20.6 x | -13.3 x | -2.35 x | -7.21 x | -8.76 x | -11.9 x | -14.4 x | -42.5 x |
| FCF Yield | -4.85% | -7.54% | -42.5% | -13.9% | -11.4% | -8.41% | -6.96% | -2.35% |
| Price to Book | 5.88 x | 6.05 x | 1.88 x | 3.62 x | 3.7 x | 10 x | 8.27 x | 12.6 x |
| Nbr of stocks (in thousands) | 51,044 | 56,933 | 58,481 | 67,576 | 80,123 | 82,226 | - | - |
| Reference price 2 | 62.24 | 57.07 | 9.770 | 16.39 | 16.13 | 25.38 | 25.38 | 25.38 |
| Announcement Date | 09/03/20 | 09/02/21 | 08/02/22 | 07/02/23 | 06/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25 | 42.09 | 96.15 | 134 | 163.4 | 201.6 | 263.6 | 374.5 |
| EBITDA | -199.9 | -268.9 | -297.1 | -179.8 | -208.9 | - | - | - |
| EBIT 1 | -200.7 | -271.2 | -300.1 | -182.7 | -211 | -203.4 | -176.5 | -113.4 |
| Operating Margin | -802.9% | -644.36% | -312.1% | -136.32% | -129.14% | -100.9% | -66.94% | -30.28% |
| Earnings before Tax (EBT) 1 | -192.3 | -266.5 | -300 | -178.2 | -194.5 | -189.1 | -152.6 | -78.84 |
| Net income 1 | -192.3 | -266.5 | -300 | -178.9 | -194.9 | -196.2 | -156.3 | -71.18 |
| Net margin | -769.02% | -633.19% | -311.98% | -133.49% | -119.34% | -97.33% | -59.3% | -19% |
| EPS 2 | -4.480 | -4.780 | -5.160 | -2.370 | -2.290 | -2.182 | -1.652 | -0.7312 |
| Free Cash Flow 1 | -154.2 | -245 | -242.8 | -153.7 | -147.5 | -175.6 | -145.2 | -49.05 |
| FCF margin | -616.92% | -582.13% | -252.52% | -114.67% | -90.28% | -87.12% | -55.09% | -13.1% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 09/03/20 | 09/02/21 | 08/02/22 | 07/02/23 | 06/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.22 | 24.2 | 29.22 | 32.49 | 35.97 | 36.34 | 33.44 | 38.3 | 43.31 | 48.3 | 46.2 | 48.71 | 52.71 | 53.96 | 48.58 |
| EBITDA | -78.91 | -87.62 | -46.11 | -42.97 | -44.14 | -46.56 | -52.65 | - | - | -50.78 | - | - | - | - | - |
| EBIT 1 | -79.67 | -88.4 | -46.89 | -43.79 | -44.88 | -47.16 | -53.26 | -52.78 | -53.69 | -51.24 | -51.25 | -51.42 | -49.4 | -51.18 | -48.59 |
| Operating Margin | -343.1% | -365.31% | -160.46% | -134.76% | -124.76% | -129.76% | -159.24% | -137.78% | -123.95% | -106.09% | -110.95% | -105.57% | -93.71% | -94.86% | -100% |
| Earnings before Tax (EBT) 1 | -79.84 | -88.4 | -46.89 | -43.06 | -43.04 | -45.23 | -49.61 | -48.56 | -49.58 | -46.76 | -48.49 | -48 | -45.42 | -47.13 | -44.11 |
| Net income 1 | -79.84 | -88.4 | -46.89 | -43.06 | -43.04 | -45.93 | -49.61 | -48.56 | -49.58 | -47.19 | -49.15 | -49.45 | -47.81 | -49.71 | -44.11 |
| Net margin | -343.83% | -365.28% | -160.46% | -132.52% | -119.65% | -126.38% | -148.33% | -126.78% | -114.47% | -97.71% | -106.39% | -101.52% | -90.7% | -92.12% | -90.79% |
| EPS 2 | -1.370 | -1.510 | -0.8000 | -0.6000 | -0.5500 | -0.6000 | -0.6000 | -0.5700 | -0.5800 | -0.5400 | -0.5556 | -0.5578 | -0.5233 | -0.5411 | -0.4600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 02/11/21 | 08/02/22 | 04/05/22 | 04/08/22 | 03/11/22 | 07/02/23 | 03/05/23 | 09/08/23 | 30/10/23 | 06/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 580 | 552 | 87.1 | 64.7 | 80 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -154 | -245 | -243 | -154 | -147 | -176 | -145 | -49.1 |
| ROE (net income / shareholders' equity) | -46.5% | -48.9% | -70.7% | -55.4% | -56.3% | -84% | -52% | -55% |
| ROA (Net income/ Total Assets) | -41% | -42.1% | -56% | -40.5% | -42% | - | - | - |
| Assets 1 | 469 | 632.4 | 536 | 441.8 | 463.8 | - | - | - |
| Book Value Per Share 2 | 10.60 | 9.440 | 5.200 | 4.530 | 4.360 | 2.530 | 3.070 | 2.020 |
| Cash Flow per Share | -3.480 | - | - | - | - | - | - | - |
| Capex 1 | 4.94 | 5.32 | 1.97 | 0.84 | 0.78 | 2.43 | 2.97 | 3.52 |
| Capex / Sales | 19.74% | 12.63% | 2.05% | 0.63% | 0.48% | 1.2% | 1.13% | 0.94% |
| Announcement Date | 09/03/20 | 09/02/21 | 08/02/22 | 07/02/23 | 06/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
25.38
USD
Average target price
26.38
USD
Spread / Average Target
+3.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.35% | 2.09B | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- DCPH Stock
- Financials Deciphera Pharmaceuticals, Inc.